Search
Tralesinidase alfa
go.drugbank.com/drugs/DB17657InvestigationalTralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2. … It is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B.[A258828]
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. … ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
(R)-warfarin
go.drugbank.com/drugs/DB08496ExperimentalS-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A1038] … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.
5-deoxyflavanone
go.drugbank.com/drugs/DB03601ExperimentalThese are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3. … 5-deoxyflavanone is a solid. This compound belongs to the flavanones.
Canosimibe
go.drugbank.com/drugs/DB19723InvestigationalCanosimibe is a small molecule drug. … Canosimibe has a monoisotopic molecular weight of 809.43 Da.
Rintodestrant
go.drugbank.com/drugs/DB21472InvestigationalRintodestrant is a small molecule drug. … Rintodestrant has a monoisotopic molecular weight of 462.09 Da.
Didanosine
go.drugbank.com/drugs/DB00900ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. … Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative
Products: Videx Chewable Dispersible Tab 25mg, Videx Chewable Dispersible Tab 100mgNOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.
Tarenflurbil
go.drugbank.com/drugs/DB05289InvestigationalTarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. … It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models.
Rocatinlimab
go.drugbank.com/drugs/DB18809InvestigationalDespite its promising results, the long-term safety of rocatinlimab requires further investigation, as serious adverse events and injection reactions such as fever and chills have been reported. … In clinical trials, it has shown significant efficacy and safety compared to a placebo.